Karine Vialatte

发表

Preclinical Toxicity, Toxicokinetics, and Antitumoral Efficacy Studies of DTS-201, a Tumor-Selective Peptidic Prodrug of Doxorubicin

P. Rochaix, C. Nicolazzi, J. Delord, 2008, Clinical Cancer Research.

Results of a phase I study of DTS-201, a peptidic prodrug of doxorubicin, in patients with solid tumors

J. Robert, S. Faivre, E. Brain, 2007 .